ArticleScientific reports2025
Further characterisation of immortalised human lymphatic endothelial cells to explore their transcriptomic profile and VEGFC response.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In vitro modelling relies on the availability of suitable cell types that accurately represent the organs under study. In lymphatic research, human dermal lymphatic endothelial cells represent the "gold standard", even though they lose their identity and proliferative capacity over time. A recently established immortalised lymphatic endothelial cell line (imLEC) could become a promising new tool for lymphatic disease modelling. We further characterised this cell line by comparing imLECs and HDLECs in terms of the expression of proteins essential for correct lymphatic function, and the proliferation, migration and sprouting responses to vascular endothelial growth factor C (VEGFC). We show similarities in the expression of lymphatic markers and VEGFC-driven cellular responses, supporting imLECs can retain their VEGFC-driven lymphangiogenic capacity without losing their lymphatic identity. RNA sequencing, however, revealed certain transcriptional differences in genes regulating lymphatic function in health and disease, highlighting the need for further validation at single gene level or specific lymphatic-associated signalling pathways. We acknowledge these limitations should be considered in future applications. Nonetheless, we believe that imLECs represent a useful model for the development of gene editing techniques allowing better modelling of lymphatic disease-associated genetic variants, ensuring long-term culture and providing higher reproducibility in genotype-phenotype validation analyses.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.